Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
6
×
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
6
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
cancer immunotherapy
clinical trials
deals
gene therapy
immunotherapy
startups
alzheimer's disease
amgen
biogen
What
bio
roundup
acquisitions
ceo
drug
biggest
daniel
gilead
o’day
sciences
abbvie’s
ahead
albert
american
announced
annual
approval
ash
biofourmis
biogen’s
biopharmaceutical
blood
borne
bourla
bucks
build
buy
cancer
cancers
celebrate
chance
collabs
companies
company
company’s
conference
convo
corner
covid
crispr
Language
unset
unknown
Current search:
abbvie
×
" seattle blog main "
×
" national top stories "
×
" gilead sciences "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More